Abliva AB (publ) (STO: ABLI)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.192
-0.001 (-0.42%)
Aug 30, 2024, 5:22 PM CET
-12.82%
Market Cap 309.16M
Revenue (ttm) 137.00K
Net Income (ttm) -102.12M
Shares Out 1.61B
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 718,058
Open 0.189
Previous Close 0.193
Day's Range 0.189 - 0.193
52-Week Range 0.114 - 0.340
Beta 1.36
Analysts n/a
Price Target n/a
Earnings Date Nov 21, 2024

About Abliva AB

Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yung... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ABLI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.